The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate whether there is a difference in endothelial function, heart rate variability and carotid intimal media thickness in patients with coronary artery disease who are receiving fish oil therapy.
One hundred patients with established coronary artery disease by coronary angiography will undergo randomization for enrollment in the study. Baseline evaluation will include assessment of brachial artery endothelial function, heart rate variability and carotid intimal media thickness. Evaluation of the endothelial function of the brachial artery will be elucidated by inflation of a blood pressure cuff around the arm for five minutes and measuring blood vessel dynamics after release of the cuff. Heart rate variability will be evaluated by 24 hour holter monitoring and analysis by standard protocol. Carotid intimal media thickness will be evaluated by ultrasound measurements guided by predetermined protocol. Patients will then be randomized to a highly purified fish oil, Omacor, 1 gram twice a day or placebo. Brachial artery ultrasound and holter monitoring will be repeated at 2 months. Carotid ultrasound will be repeated at the end of the study at 12 months.
| Condition | Intervention |
|---|---|
|
Coronary Artery Disease |
Drug: Omacor (omega-3-acid ethyl esters) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease |
- Percent change in flow-mediated vasodilation by brachial artery ultrasound at 2 months
- Change in heart rate variability indices at 2 months
- Percent change in carotid intimal media thickness at 12 months
- Change in QT dispersion interval at 2 months
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2006 |
| Estimated Study Completion Date: | July 2008 |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Established coronary artery disease as determined by coronary angiography within the last 5 years demonstrating at least 50% stenosis in one of the major coronary vessels
- Age >18 and <75.
Exclusion Criteria:
- Baseline fish oil intake ≥1g/day or fish intake >100g/day
- Need for urgent or emergent CABG
- Contraindication for plavix, aspirin or statin
- Gastrointestinal malabsorption syndrome
- Pregnancy
- Oral contraceptive use
- Ejection fraction <40%
- Underlying atrial or ventricular arrhythmia
- History of rheumatoid arthritis
Contacts and Locations| Contact: Sheba K Meymandi, M.D.,FACC | 818-364-4287 | smeymandi@ladhs.org |
| Contact: Mahmoud I Traina, M.D. | 818-364-4287 | mitraina@gmail.com |
| United States, California | |
| OV-UCLA Medical Center | Recruiting |
| Sylmar, California, United States, 91342 | |
| Principal Investigator: | Sheba K Meymandi, M.D., FACC | University of California, Los Angeles |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00454493 History of Changes |
| Other Study ID Numbers: | 05H-561610 |
| Study First Received: | March 29, 2007 |
| Last Updated: | March 29, 2007 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, Los Angeles:
|
omacor fish oil omega 3 fatty acids coronary artery disease |
endothelial function heart rate variability carotid intimal media thickness QT dispersion |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases |
Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases |
ClinicalTrials.gov processed this record on May 21, 2013